A Randomized Study of Monoclonal Antibody 3F8 Plus Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Compared to 13-cis-Retinoic Acid Plus GM-CSF in High Risk Stage 4, Primary Refractory Neuroblastoma Patients.

Trial Profile

A Randomized Study of Monoclonal Antibody 3F8 Plus Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Compared to 13-cis-Retinoic Acid Plus GM-CSF in High Risk Stage 4, Primary Refractory Neuroblastoma Patients.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 05 Feb 2013

At a glance

  • Drugs Granulocyte-macrophage colony-stimulating factors; Isotretinoin; Monoclonal antibody 3F8
  • Indications Neuroblastoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Aug 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 16 Jan 2010 New source identified and integrated (M.D. Anderson Cancer Center).
    • 10 Sep 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top